{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":81},"studies":[{"active":true,"description":"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
","eudractNumber":null,"id":9261,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-02-15T13:25:54+01:00","shortTitle":"Privigen","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

NAFLD Kohorte Dr. Rau - Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung\n(Fettleberkohorte)

","eudractNumber":null,"id":2264,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-10-01T09:56:17+02:00","shortTitle":"Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung (Fettleberkohorte)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting","eudractNumber":null,"id":10657,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-04-24T09:00:30+02:00","shortTitle":"Prosperity","therapeutical":false,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Qualitätssicherung der Therapie des Ovarialkarzinoms (QS-OVAR) 
DRKS00027253
DRKS00027253DRKS00027253
","eudractNumber":null,"id":8573,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-03T12:47:13+02:00","shortTitle":"QS - OVAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation of Clinical Management and Outcome in High\nRisk or Recurrent Endometrial Cancer - A Real-World \nObservational Study (QS-Endometrium) ","eudractNumber":null,"id":11933,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-27T09:48:22+01:00","shortTitle":"QS-Endometrium","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Radical antegrade modular pancreatosplenectomy versus conventional
distal pancreatosplenectomy for pancreatic cancer – The multicenter,
randomized controlled RAMPS-Trial
","eudractNumber":null,"id":11072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-01T13:19:44+02:00","shortTitle":"RAMPS trial","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting","eudractNumber":null,"id":9253,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-03T13:01:22+01:00","shortTitle":"Reality 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes

DRKS00009536
","eudractNumber":null,"id":1491,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-04-01T14:01:18+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer

DRKS00009536

","eudractNumber":null,"id":6191,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-09-08T13:56:24+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)","eudractNumber":null,"id":10995,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05573893","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-18T09:19:32+02:00","shortTitle":"Registerstudie PROVIDENCE","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?lang=de&page=6&pfs=ph_2&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
\",\"name\":\"Privigen\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9261\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

NAFLD Kohorte Dr. Rau - Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung\\n(Fettleberkohorte)

\",\"name\":\"Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung (Fettleberkohorte)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/2264\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting\",\"name\":\"Prosperity\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10657\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Qualitätssicherung der Therapie des Ovarialkarzinoms (QS-OVAR) 
DRKS00027253
DRKS00027253DRKS00027253
\",\"name\":\"QS - OVAR\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8573\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Evaluation of Clinical Management and Outcome in High\\nRisk or Recurrent Endometrial Cancer - A Real-World \\nObservational Study (QS-Endometrium) \",\"name\":\"QS-Endometrium\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11933\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
Radical antegrade modular pancreatosplenectomy versus conventional
distal pancreatosplenectomy for pancreatic cancer – The multicenter,
randomized controlled RAMPS-Trial
\",\"name\":\"RAMPS trial\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11072\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting\",\"name\":\"Reality 2\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9253\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes

DRKS00009536
\",\"name\":\"Registerstudie Mammakarzinom des Mannes\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/1491\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer

DRKS00009536

\",\"name\":\"Registerstudie Mammakarzinom des Mannes\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6191\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)\",\"name\":\"Registerstudie PROVIDENCE\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10995\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=7&pfs=ph_2\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}